VRTX VERTEX PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, VERTEX PHARMACEUTICALS INC reported revenue of $3.33B (up 12.5% from a year earlier), net income of $1.10B and diluted EPS of $4.31; over the last four quarters revenue was $12.6B and net income $4.41B; for the fiscal year ended December 2025 revenue was $12.0B, up 8.9% on the year before.

VRTX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $12.0B, gross profit n/a, operating income $4.17B, net income $3.95B (margin 32.9%), EPS $15.32
• Fiscal year ended Dec 2024: revenue $11.0B, gross profit n/a, operating income −$233M, net income −$536M (margin -4.9%), EPS −$2.08
• Fiscal year ended Dec 2023: revenue $9.87B, gross profit n/a, operating income $3.83B, net income $3.62B (margin 36.7%), EPS $13.89
• Fiscal year ended Dec 2022: revenue $8.93B, gross profit n/a, operating income $4.31B, net income $3.32B (margin 37.2%), EPS $12.82
• Fiscal year ended Dec 2021: revenue $7.57B, gross profit n/a, operating income $2.78B, net income $2.34B (margin 30.9%), EPS $9.01

VRTX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $3.33B (up 12.5% year over year), net income $1.10B, EPS $4.31
• Quarter ended Mar 31, 2026: revenue $2.99B (up 7.8% year over year), net income $1.03B, EPS $4.02
• Quarter ended Dec 31, 2025 (from the annual report): revenue $3.19B (up 9.5% year over year), net income $1.19B, EPS $4.64
• Quarter ended Sep 30, 2025: revenue $3.08B (up 11.0% year over year), net income $1.08B, EPS $4.20
• Quarter ended Jun 30, 2025: revenue $2.96B (up 12.1% year over year), net income $1.03B, EPS $3.99
• Quarter ended Mar 31, 2025: revenue $2.77B (up 3.0% year over year), net income $646M, EPS $2.49
• Quarter ended Dec 31, 2024 (from the annual report): revenue $2.91B (up 15.7% year over year), net income $913M, EPS $3.62
• Quarter ended Sep 30, 2024: revenue $2.77B (up 11.6% year over year), net income $1.05B, EPS $4.01
• Quarter ended Jun 30, 2024: revenue $2.65B (up 6.1% year over year), net income −$3.59B, EPS −$13.92
• Quarter ended Mar 31, 2024: revenue $2.69B (up 13.3% year over year), net income $1.10B, EPS $4.21
• Quarter ended Dec 31, 2023 (from the annual report): revenue $2.52B (up 9.3% year over year), net income $969M, EPS $3.71
• Quarter ended Sep 30, 2023: revenue $2.48B (up 6.4% year over year), net income $1.04B, EPS $3.97
• Quarter ended Jun 30, 2023: revenue $2.49B (up 13.5% year over year), net income $916M, EPS $3.52
• Quarter ended Mar 31, 2023: revenue $2.37B (up 13.2% year over year), net income $700M, EPS $2.69
• Quarter ended Dec 31, 2022 (from the annual report): revenue $2.30B (up 11.1% year over year), net income $819M, EPS $3.14
• Quarter ended Sep 30, 2022: revenue $2.33B (up 17.7% year over year), net income $931M, EPS $3.59
• Quarter ended Jun 30, 2022: revenue $2.20B (up 22.5% year over year), net income $811M, EPS $3.13
• Quarter ended Mar 31, 2022: revenue $2.10B (up 21.6% year over year), net income $762M, EPS $2.96
• Quarter ended Dec 31, 2021 (from the annual report): revenue $2.07B, net income $770M, EPS $2.98
• Quarter ended Sep 30, 2021: revenue $1.98B, net income $852M, EPS $3.28

VRTX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $3.63B, share buybacks $2.02B
• Fiscal year ended Dec 2024: operating cash flow −$493M, share buybacks $1.18B
• Fiscal year ended Dec 2023: operating cash flow $3.54B, share buybacks $428M
• Fiscal year ended Dec 2022: operating cash flow $4.13B, share buybacks $0
• Fiscal year ended Dec 2021: operating cash flow $2.64B, share buybacks $1.43B

VRTX balance sheet

• Jun 30, 2026: cash $6.14B, total assets $27.4B, total liabilities $7.18B, shareholders' equity $20.2B
• Mar 31, 2026: cash $5.49B, total assets $26.5B, total liabilities $7.12B, shareholders' equity $19.4B
• Dec 31, 2025: cash $5.08B, total assets $25.6B, total liabilities $6.98B, shareholders' equity $18.7B
• Sep 30, 2025: cash $4.94B, total assets $24.9B, total liabilities $7.54B, shareholders' equity $17.3B
• Jun 30, 2025: cash $4.97B, total assets $24.0B, total liabilities $6.86B, shareholders' equity $17.2B
• Mar 31, 2025: cash $4.67B, total assets $22.9B, total liabilities $6.38B, shareholders' equity $16.5B
• Dec 31, 2024: cash $4.57B, total assets $22.5B, total liabilities $6.12B, shareholders' equity $16.4B
• Sep 30, 2024: cash $5.24B, total assets $22.2B, total liabilities $6.61B, shareholders' equity $15.6B

What is VRTX's revenue?

VERTEX PHARMACEUTICALS INC reported $12.6B of revenue over its last four quarters, through June 30, 2026.

Is VRTX profitable?

Yes. VERTEX PHARMACEUTICALS INC earned $4.41B over the last four quarters.

What is VRTX's EPS?

Diluted earnings per share over the last four quarters were $17.17; $4.31 in the latest quarter.

VRTX ownership and insider trades · All stocks